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Abstract
Importance—Effects of modern high-deductible health plans (HDHP) on chronically ill patients 
and adverse outcomes are unknown.
Objective—Determine HDHP effects on high-priority diabetes outpatient care and preventable 
acute complications.
Design—Controlled interrupted-time-series.
Setting—A large national health insurer from 2003–2012.
Participants—12,084 HDHP members with diabetes age 12–64. HDHP members were enrolled 
for one year in a low-deductible (≤$500) plan followed by two years in a HDHP (≥$1000) after an 
employer-mandated switch. Patients transitioning to HDHPs were propensity-score-matched with 
contemporaneous patients whose employers offered only low-deductible coverage. Low-income 
(n=4121) and health savings account (HSA)-eligible (n=1899) diabetes patients were subgroups of 
interest.
Exposure—Employer-mandated HDHP transition.
Main Outcomes and Measures—High-priority outpatient visits, disease monitoring tests, and 
outpatient and emergency department visits for preventable acute diabetes complications.
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Results—The overall, low-income, and HSA-eligible diabetes HDHP groups experienced 
increases in out-of-pocket medical expenditures of 49.4% (40.3%,58.4%), 51.7% (38.6%,64.7%), 
and 67.8% (47.9%,87.8%), respectively, relative to controls in the year after transitioning to 
HDHPs. High-priority primary care visits and disease monitoring tests did not change significantly 
in the overall HDHP cohort while high-priority specialist visits declined by 5.5% (−9.6%,−1.5%) 
and 7.1% (−11.5%,−2.7%) in follow-up years 1 and 2 versus baseline, respectively. Outpatient 
acute diabetes complication visits were delayed in the overall and low-income HDHP cohorts at 
follow-up (adjusted hazard ratios: 0.94 [0.88,0.99] and 0.89 [0.81,0.98], respectively). The overall, 
low-income, and HSA-eligible diabetes HDHP groups experienced increased emergency 
department acute complication visits of 8.0% (4.6%,11.4%), 21.7% (14.5%,28.9%), and 15.5% 
(10.5%,20.6%) per year, respectively.
Conclusions and Relevance—Diabetes patients experienced minimal changes in outpatient 
visits and disease monitoring after a HDHP switch, but low-income and HSA-eligible HDHP 
members experienced major increases in emergency department visits for preventable acute 
diabetes complications.
High-deductible health plans (HDHP) will soon be the predominant commercial health 
insurance arrangement in the US.1 HDHPs require potential annual out-of-pocket spending 
of approximately $1000–$6000 per person for most non-preventive services; in 2015, 46% 
of covered workers had deductibles of $1000 or more, while 19% had deductibles of $2000 
or more.1
Diabetes is a major cause of morbidity and premature death in the US.2,3 High cost-sharing 
might especially affect chronically ill patients who require frequent and expensive services. 
However, effects of HDHPs on outpatient care patterns and adverse outcomes among 
chronically ill patients are unknown.
We hypothesized that some outpatient care, including preventive tests that are inexpensive 
even under HDHPs, would remain stable among HDHP members with diabetes. We further 
hypothesized that relatively expensive care such as specialist visits and outpatient visits for 
acute complications (paid out-of-pocket until the deductible is met), would decline or be 




We drew our study population from commercially insured members in the Optum database 
(Eden Prairie, MN) enrolled between 1/2003–12/2012. Data comprised enrollment tables 
and all medical, pharmacy, and hospitalization claims from members of a large national 
health plan. We included members in the study based on their employers’ health insurance 
offerings. We defined employers with low- and high-deductible coverage as those offering 
exclusively annual deductibles of ≤$500 or ≥$1000, respectively (eAppendix). To determine 
employer annual deductibles, we used a benefits variable that was available for most smaller 
employers (approximately ≤100 employees, representing 57.7% of account years) that 
included information such as in-network and out-of-network deductible, copayment, and co-
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insurance. For larger employers (42.4% of account years), we imputed deductible levels 
using out-of-pocket spending among employees who utilized health services, an algorithm 
that had 96.2% sensitivity and 97.0% specificity (eTable-1).
Both low- and high-deductible plans often cover a single annual preventive primary care 
visit and disease monitoring such as hemoglobin A1c testing at low or no out-of-pocket 
cost.1 In contrast, HDHP members on average must pay substantially higher amounts than 
low-deductible members for specialist, acute care, and ED visits.
Our study groups were drawn from individuals whose employers mandated a HDHP switch 
(HDHP group) or mandated continuation in low-deductible plans (control group), 
minimizing self-selection. We required HDHP group members to have 12 baseline months in 
a low-deductible plan followed by 24 months in an HDHP after the employer-mandated 
HDHP switch (36 continuous enrollment months per member). We defined the beginning of 
the month of the low-to-high deductible transition as the index date. We identified all 
potential control group members whose employers offered only low-deductible plans over at 
least a 3-year period (n=1,674,527).
To further minimize potential selection effects, especially at the employer level, we used a 
two-level (employer- and member-level) propensity score matching approach4,5 (eAppendix) 
and estimated propensity scores predicting the likelihood of a mandated HDHP switch. After 
matching at the employer level on multiple characteristics (eAppendix), we identified 
diabetes patients age 12–64 using a standard claims-based algorithm (eTable-2; n=12,854 
HDHP and 69,749 control pool members [Table 1]). We included patients who first met the 
diabetes diagnosis algorithm criteria between 6 months before to 6 months after the 
beginning of the baseline year. Less than half a percent of members in the HDHP and 
control pool had missing census-derived characteristics (Table 1) and were excluded from 
the propensity score match.
Within quartiles of the employer propensity score, we matched HDHP members with 
diabetes at the patient-level 1:1 to controls with diabetes based on age, gender, race/
ethnicity, neighborhood poverty and education, US region, Adjusted Clinical Groups 
(ACG)-morbidity score,6,7 month of first diabetes diagnosis, employer size, and index 
month. We also matched on baseline quarterly numbers of high-priority (defined below) 
primary care and specialist visits, preventable acute diabetes complication visits (defined 
below), ED visits, hospitalization days, and baseline quarterly total out-of-pocket spending 
per member.8,9 Compared with the unmatched sample, our propensity score matching 
approach increased the similarity of the HDHP and control groups with respect to age, 
gender, neighborhood poverty level, morbidity score, baseline outpatient copayment, and 
employer size (Table 1). Our final group included 12,084 HDHP members with diabetes and 
their 1:1 matched controls.
Our primary subgroups of interest, based on previous evidence of adverse HDHP 
effects,10,11 included high-morbidity and low-income diabetes patients (defined below; 
n=3640 and 4121 per group, respectively). We also assessed HDHP members who were 
eligible to have health savings accounts (HSA) because such plans are rapidly increasing in 
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prevalence and have the highest out-of-pocket obligations among commercial insurance 
plans.1 HSAs allow pre-tax contributions from employers or members, funds that can be 
used to pay for qualified medical expenses.12
Design
We used a before-after with comparison group design, a controlled time-to-event design 
applied to the baseline and follow-up periods, or a controlled cumulative monthly 
interrupted-time-series design depending on the outcome type.
Measures
Utilization and Disease Monitoring Measures—We used standard algorithms for 
detecting outpatient visits with Current Procedural Terminology (CPT®) evaluation and 
management codes and a provider type variable to classify visits as primary care or 
specialist. We then applied a taxonomy developed by Fenton and colleagues13 (eAppendix) 
to characterize each office visit as “high-priority” or “low-priority” based on the primary 
diagnosis. High-priority diagnoses are considered more likely to benefit from medical care, 
although the measure is not intended to reflect the appropriateness of particular visits. We 
captured outpatient disease monitoring measures based on Healthcare Effectiveness Data 
and Information Set (HEDIS)14 specifications, including ≥1 annual: primary care visit; 
hemoglobin A1c, low-density lipid cholesterol (LDL-C), and microalbumin test; and retinal 
eye exam (eTable-3).
Health Outcome Measures—To assess whether HDHPs were associated with changes in 
time-sensitive care, two clinicians on our team (J.F.W and E.M.E) used a systematic 
approach to develop a measure of outpatient and ED visits that could indicate a preventable 
acute diabetes complication (eAppendix, hereafter, “complication visits”). We defined acute 
diabetes complications as symptoms or conditions (when coded by clinicians as the primary 
diagnosis) that could be associated with delaying recommended or urgent diabetes-related 
outpatient or ED care (including prescription drug use) for up to 4 months and that require 
timely care by medical professionals. We validated this measure in our population (eTables 5 
and 6) by determining that outpatient and ED visits with these complication diagnoses were 
associated with odds ratios of 4.10 (3.98, 4.23) and 3.02 (2.96, 3.08), respectively, of 
subsequent hospitalization compared with other types of outpatient or ED visits. The 5 most 
common categories of outpatient complication visits at baseline, accounting for 82.0% of 
such visits, were cellulitis, urinary tract infection, angina and ischemic heart disease, acute 
cerebrovascular disease, and pneumonia. The 5 most common categories of ED 
complication visits at baseline, accounting for 62.0% of such visits, were cellulitis, urinary 
tract infection, hypo/hyperglycemia and their major acute complications, angina and 
ischemic heart disease, and pneumonia.
We summed all healthcare expenditures (i.e., paid by the health plan and patient) during the 
7 days following an acute complication visit to the ED as a health outcome measure to 
assess intensity of and need for diagnostic and therapeutic services. That is, we included this 
as a proxy to indicate level of “sickness” at presentation to the ED.
Wharam et al. Page 4














We applied the Johns Hopkins ACG® System comorbidity score (ACG, version 10.0.1) 
algorithm, a validated measure that predicts mortality,6,15 to members’ baseline year to 
estimate comorbidity, and defined high- and low-morbidity as ACG scores of ≥3.0 and <2.0, 
respectively. Using 2000 US Census block data and validated methods,16,17 we defined 
members as high- and low-income based on living in neighborhoods with below-poverty-
levels of <5% and ≥10%, respectively, and used a similar approach to categorize education 
levels.16–21 We classified members as white, black, Hispanic, Asian, or other based on a 
combination of geocoding and surname analysis (eAppendix).22,23 Other covariates included 
age category (12–25, 26–45, ≥ 40–64 years), gender, and US region (West, Midwest, South, 
Northeast).
Analysis
We compared baseline characteristics of our study groups using chi-squared tests, t-tests, 
and non-parametric tests.24 In all statistical models estimating HDHP effects, we removed 
from analyses the month before and after the index date to reduce bias due to anticipatory 
increases in utilization prior to the HDHP switch (and consequent reductions in the month 
after the switch).
For the high priority primary care and specialist visit outcomes, we first fit interrupted-time-
series models25 in order to both visually display monthly trends and confirm that the study 
groups did not have differential baseline trends, a key assumption of difference-in-
differences analysis. We then used difference-in-differences analysis to examine changes in 
annual high-priority outpatient visits and disease monitoring measures. We applied 
generalized estimating equations26,27 models with a negative binomial distribution for 
outpatient visits and a binary distribution for disease monitoring measures, controlling for 
age, gender, race/ethnicity, education level, poverty level, US region, ACG score, employer 
size, and index date.
To examine time to first outpatient and ED visits for acute complications, we used separate 
Cox proportional hazards regression models for the baseline and follow-up periods, 
adjusting for the same covariates as above.
To analyze annual changes in complication visits and subsequent 7-day total expenditures, 
we applied aggregate-level segmented regression to cumulative rates that had been adjusted 
for the above covariates (eAppendix).
Using the same methods and outcomes, we conducted subgroup analyses stratified by low 
and high-income and morbidity, and examined HSA-eligible members and their matched 
pairs. We also assessed several other subgroups of interest including those defined by other 
income cutoffs (residing in neighborhoods with under 10%, over 5%, and over 20% of 
households below the Federal poverty level), and residents of predominantly white and non-
white race neighborhoods. As a sensitivity analysis, we restricted the sample to members 
age 18–64, re-matched, then analyzed all primary outcomes.
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The average age of HDHP and control members was 50 and 45% in each group were female 
(Table 1). 35% in both groups lived in low-income neighborhoods, 25% lived in low-
education neighborhoods, 11–12% were Hispanic members, and the mean ACG morbidity 
score was 2.8 (standard deviation ~3.6). At baseline, HDHP and control members had 
unadjusted mean high-priority primary care visit rates of 2.04 and 2.05 (p=0.69) per member 
per year, respectively, and corresponding high-priority specialist visit rates of 1.38 and 1.38 
(p=0.94), respectively.
Changes in Out-of-Pocket Exposure
The overall, low-morbidity, high-morbidity, high-income, low-income, and HSA diabetes 
HDHP groups experienced increases in mean out-of-pocket medical expenditures of 49.4% 
(40.3%,58.4%; absolute: $374.6), 56.8% (45.8%,67.8%; absolute: $292.0), 40.9% (31.5%,
50.4%; absolute: $448.8), 48.4% (37.2%,59.6%; absolute: $361.8), 51.7% (38.6%,64.7%; 
absolute: $400.4), and 67.8% (47.9%,87.8%; absolute: $463.0), respectively, relative to 
controls in the year after transitioning to HDHPs (eTable-7). Out-of-pocket obligations for 
hemoglobin A1c, LDL-C, and microalbumin tests increased from a mean of $1.2–$1.4 at 
baseline among HDHP members to $2.2–$4.8 at follow-up (eTable-8). Primary care visit 
costs increased from $15.4 to $23.3–$26.8 from baseline to follow-up among HDHP 
members, while specialist visits averaged $23.3 at baseline and approximately $42 at follow-
up.
Utilization and Disease Monitoring Measures
In adjusted difference-in-differences analyses, only the low-morbidity, high-income, and 
low-income HDHP subgroups experienced baseline-to-follow-up year 2 changes in high-
priority primary care visits of −5.1% (−8.6%,−1.6%), −5.7% (−10.5%,−0.9%), and −5.2% 
(−9.8%,−0.7%), respectively (Table 2; eFigure-2).
High-priority specialist visits declined in the overall HDHP cohort by 5.5% (−9.6%,−1.5%) 
and 7.1% (−11.5%,−2.7%) in follow-up years 1 and 2 versus baseline, respectively. Among 
the low- and high-morbidity HDHP subgroups compared with controls, year 2 versus 
baseline changes in high-priority specialist visits were −7.9% (−14.4%,−1.4%) and −12.2% 
(−17.9%,−6.5%), respectively. Corresponding changes among high- and low-income HDHP 
members were −10.7% (−17.1%,−4.3%) and −7.6% (−15.9%,0.7%).
By follow-up year 2, we did not detect any changes in disease monitoring measures 
including annual primary care visits (relative change: −0.2% [−1.4%,0.9%]); hemoglobin 
A1c (−0.8% [−2.6%,1.0%]), LDL-C (−1.6% [−3.6%,0.5%]), and microalbumin (−0.7% 
[−4.7%,3.4%]) tests; and retinal eye exams (0.9% [−3.4%,5.1%]), patterns that were similar 
across all subgroups (Table 3).
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The overall HDHP diabetes cohort experienced a follow-up period delay in time to first 
outpatient complication visit relative to controls (adjusted hazard ratio, aHR: 0.94 
[0.88,0.99]; eTable-15 and eFigure-3) that was not present at baseline (aHR: 1.01 
[0.93,1.09]). Total annual ED complication visits and complication episode expenditures 
increased by 8.0% (4.6%,11.4%) and 5.6% (3.8%,7.3%) in the overall HDHP group relative 
to controls (eTables 16 and 17, eFigure-3).
Among key HDHP subgroups, high-morbidity HDHP members experienced a follow-up 
period delay in first outpatient complication visits (aHR 0.89 [0.82,0.97]; Figure 2 and 
eTable-16) and increased annual total expenditures for ED complication episodes (adjusted 
relative change: 12.1% [7.2%,17.0%]; eTable-17).
Low-income HDHP members also delayed first outpatient complication visits at follow-up 
(0.89 [0.81,0.98], Figure 3 and eTable-16), experienced an acceleration in first ED 
complication visits that approached statistical significance (aHR: 1.14 [0.98,1.33]), had 
increased total ED complication visits (21.7% [14.5%,28.9%]), and increased total 
expenditures for ED episodes (9.5% [6.5%,12.5%]). Corresponding changes in these ED 
outcomes among HSA HDHP members were 15.5% (10.5%,20.6%) and 29.6% ([19.0%,
40.1%]; eFigure-5 and eTable-17).
Sensitivity analyses (eAppendix) did not change interpretation of our main findings and 
results are included in eTables 10,11,13–19; and eFigure-4).
DISCUSSION
HDHP members with diabetes experienced minimal changes in high-priority outpatient 
visits and disease monitoring measures, but delayed presenting for first outpatient 
complication visits and experienced 6%–8% increases in ED complication measures. Low-
income and high-morbidity HDHP members also experienced delays in presenting for 
outpatient complication visits after the HDHP switch, and these groups as well as HSA-
HDHP members experienced moderate-to-large increases in ED acute complication visits or 
expenditures.
Our results were generally consistent with our hypotheses. Reductions in specialist visits 
were smaller than expected, but the decline in this rate might have been tempered by 
increased need for specialist care because of increased diabetes complication severity. 
Although we cannot directly determine whether delayed outpatient complication visits 
caused increased morbidity among vulnerable HDHP members, the large increases in ED 
complication episode costs we detected seems suggestive. Despite some uncertainty about 
causal mechanisms and morbidity impacts, increased acute diabetes complications and 
associated expenditures are almost certainly unintended consequences that all stakeholders 
wish to avoid. Of note, adverse HDHP effects in diabetes would have gone undetected if 
assessed using traditional HEDIS disease monitoring metrics, suggesting that health systems 
could benefit from adopting acute preventable diabetes complication measures such as the 
one we created and validated.
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Reasons for our acute complication findings may be clarified by considering effects in our 
key patient subgroups. It is likely that high-morbidity, low-income, and HSA-eligible 
diabetes patients (who experienced the largest cost-sharing increases) had significantly 
greater concerns about HDHP-related out-of-pocket spending than their less vulnerable 
HDHP counterparts. These patients might therefore attempt to minimize health expenditures 
by forgoing expensive scheduled and acute visits, or by shifting care to less expensive but 
potentially less appropriate settings. Such effects might lead to more severe disease by the 
time of presentation for acute complications. Adverse outcomes among HSA-HDHP 
members might imply that HSA funding levels were low, that patients were unaware of this 
resource, or that they engaged in inappropriate attempts to preserve HSA funds. These 
findings among subgroups suggest that a bifurcation of outpatient care could be occurring 
among HDHP members with diabetes, with less vulnerable patients largely unaffected, but 
more vulnerable patients facing access limitations that ultimately increase utilization. Future 
studies could directly assess the causal relationship between care delays and acute 
complication visits, and determine whether other factors such as medication non-adherence 
play any role.
No previous research has examined outpatient visits or complications among HDHP patients 
with diabetes. The RAND Health Insurance Experiment from 40 years ago predicted that the 
“poor and sick” would have increased long-term mortality under high-level cost sharing due 
to worsened hypertension control.11 Our study, which occurs in a different health care era 
and includes a far larger sample size, is the first to examine acute complication measures 
among chronically ill HDHP members. It adds the key finding that concerning utilization 
patterns increase soon after a HDHP switch among similarly vulnerable populations. Other 
chronically ill HDHP patients who require time-sensitive care, such as those with coronary 
heart disease, heart failure, or cancer might be at risk, but further research is warranted.
Two previous studies found minimal or no changes in several diabetes disease monitoring 
metrics;2829 similarly, we detected no changes in such measures, likely related to low out-of-
pocket costs (eTable-8) and perhaps the perceived non-discretionary nature of these tests 
(e.g., retinal eye exams). These findings should be reassuring to primary care physicians 
both because they might presage unchanged long-term disease control under HDHPs and 
also because rates of such tests are increasingly being used to measure clinician “quality.” 
Our disease monitoring results also confirm a growing body of literature demonstrating that 
excluding “high value” services such as secondary preventive tests from cost-sharing under 
HDHPs might help to preserve use.30–33
This study has several potential limitations. We did not have exact benefit coverage details 
for large employers, but we utilized a highly sensitive and specific algorithm for detecting 
their deductible levels. Furthermore, our analyses of “gold-standard” out-of-pocket 
expenditures showed that, at the population level, the HDHP group experienced increased 
out-of-pocket medical expenditures of approximately 50%, indicating the validity of our 
plan type classification. Our measure of acute complication visits is novel, but we created 
the measure rigorously and validated it extensively as described above and in the eAppendix. 
Furthermore, the top 5 diagnosis clusters (e.g., cellulitis, urinary tract infection, hypo/
hyperglycemia and their major acute complications, angina and ischemic heart disease, and 
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pneumonia) have face validity and analyses of this subset revealed similar patterns 
(eTable-19). Nevertheless, measurement error is still possible given lack of consensus 
regarding which diagnoses comprise “acute preventable diabetes complications” and the 
imprecision of ICD-9 diagnoses. We did not have information about HSA contributions, data 
that could allow determining whether such funds modify the adverse outcomes we detected. 
We also did not report changes in medication use or laboratory values (due to a high degree 
of missing values). We did not have access to health insurance premiums and therefore could 
not estimate total member expenditures (premiums plus out-of-pocket). Finally, our study is 
not representative of people with non-employer-sponsored insurance, very low 
socioeconomic status patients, members with very high deductibles, or people whose first 
exposure to insurance is under HDHPs.
We found that diabetes patients experienced minimal changes in outpatient visits and disease 
monitoring after a HDHP switch, but low-income, high-morbidity, and HSA-HDHP 
subgroups experienced major increases in ED visits or expenditures for preventable acute 
diabetes complications. These subgroups might be especially at risk in the increasingly 
HDHP-centric private US health system, and our results support a strategy of minimizing the 
enrollment of vulnerable diabetes subpopulations in HDHPs or targeting cost-sharing 
reductions such as HSA contributions to such patients.34
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Unadjusted plots of preventable acute diabetes complication measures and tables (below 
each plot) showing adjusted effect estimates, stratified by morbidity group.
Abbreviations: HDHP, high-deductible health plan; aHR, adjusted hazard ratio; CI, 
confidence interval. Note: “Total expenditures during acute complication episodes” is a 
proxy indicating overall utilization in the 7 days following emergency department visits for 
preventab le acute diabetes complications (as defined in the manuscript). Vertical blue lines 
are centered at the index date when HDHP members were switched into HDHPs. aAdjusted 
Clinical Groups score less than 2.0; bAdjusted Clinical Groups score greater than or equal to 
3.0.
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Unadjusted plots of preventable acute diabetes complication measures and tables (below 
each plot) showing adjusted effect estimates, stratified by income group.
Abbreviations: HDHP, high-deductible health plan; aHR, adjusted hazard ratio; CI, 
confidence interval. Note: “Total expenditures during acute complication episodes” is a 
proxy indicating overall utilization in the 7 days following emergency department visits for 
preventable acute diabetes complications (as defined in the manuscript). Vertical blue lines 
are centered at the index date when HDHP members were switched into HDHPs. aLiving in 
neighborhoods with below-poverty levels of less than 5%. bLiving in neighborhoods with 
below-poverty levels of 10% or greater.
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